Risk of Plasmodium vivax recurrences follows a 30-70 rule and indicates relapse heterogeneity in the population

A key characteristic of Plasmodium vivax parasites is their ability to adopt a latent liver-stage form called hypnozoites, able to cause relapse of infection months or years after a primary infection. Relapses of infection through hypnozoite activation are a major contributor to blood-stage infections in P vivax endemic regions and are thought to be influenced by factors such as febrile infections, immunity, and transmission intensity. Some of these factors may cause temporary changes in hypnozoite activation over time, leading to 'temporal heterogeneity' in reactivation risk. In addition, variation in exposure to infection may be a longer-term characteristic of individuals that leads to 'population heterogeneity' in hypnozoite activation. We analyze data on risk of P vivax in two previously published data sets from Papua New Guinea and the Thailand-Myanmar border region. Modeling different mechanisms of reactivation risk, we find strong evidence for population heterogeneity, with 30% of patients having almost 70% of all P vivax infections. Model fitting and data analysis indicates that individual variation in relapse risk is a primary source of heterogeneity of P vivax risk of recurrences.

[1]  Bruce M. Russell,et al.  Hidden Biomass of Intact Malaria Parasites in the Human Spleen. , 2021, The New England journal of medicine.

[2]  R. Price,et al.  Evaluation of splenic accumulation and colocalization of immature reticulocytes and Plasmodium vivax in asymptomatic malaria: A prospective human splenectomy study , 2021, PLoS medicine.

[3]  T. Lefèvre,et al.  Predicting the public health impact of a malaria transmission-blocking vaccine , 2021, Nature Communications.

[4]  R. Price,et al.  The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network , 2020, PLoS medicine.

[5]  Steffen S. Docken,et al.  Quantifying and preventing Plasmodium vivax recurrences in primaquine-untreated pregnant women: An observational and modeling study in Brazil , 2020, PLoS neglected tropical diseases.

[6]  R. Price,et al.  Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis , 2020, The American journal of tropical medicine and hygiene.

[7]  K. Battle,et al.  Plasmodium vivax in the Era of the Shrinking P. falciparum Map , 2020, Trends in parasitology.

[8]  Mark B. Flegg,et al.  An Activation-Clearance Model for Plasmodium vivax Malaria , 2020, Bulletin of Mathematical Biology.

[9]  C. Kocken,et al.  A dual fluorescent Plasmodium cynomolgi reporter line reveals in vitro malaria hypnozoite reactivation , 2020, Communications Biology.

[10]  C. Buckee,et al.  Resolving the cause of recurrent Plasmodium vivax malaria probabilistically , 2019, Nature Communications.

[11]  T. Bousema,et al.  Malaria Hotspots: Is There Epidemiological Evidence for Fine-Scale Spatial Targeting of Interventions? , 2019, Trends in parasitology.

[12]  M. Gabriela M. Gomes,et al.  Modelling the epidemiology of residual Plasmodium vivax malaria in a heterogeneous host population: A case study in the Amazon Basin , 2019, bioRxiv.

[13]  Su Yun Kang,et al.  Pareto rules for malaria super-spreaders and super-spreading , 2019, Nature Communications.

[14]  H. Win,et al.  Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  H. Win,et al.  Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  L. Robinson,et al.  The complex relationship of exposure to new Plasmodium infections and incidence of clinical malaria in Papua New Guinea , 2017, eLife.

[17]  Quique Bassat,et al.  Key Knowledge Gaps for Plasmodium vivax Control and Elimination , 2016, The American journal of tropical medicine and hygiene.

[18]  A. Ghani,et al.  Variation in relapse frequency and the transmission potential of Plasmodium vivax malaria , 2016, Proceedings of the Royal Society B: Biological Sciences.

[19]  Q. Bassat,et al.  Strategies for Understanding and Reducing the Plasmodium vivax and Plasmodium ovale Hypnozoite Reservoir in Papua New Guinean Children: A Randomised Placebo-Controlled Trial and Mathematical Model , 2015, PLoS medicine.

[20]  R. Price,et al.  A systematic review of sub-microscopic Plasmodium vivax infection , 2015, Malaria Journal.

[21]  M. Davenport,et al.  Modeling the Dynamics of Plasmodium vivax Infection and Hypnozoite Reactivation In Vivo , 2015, PLoS neglected tropical diseases.

[22]  S. Hay,et al.  Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission , 2014, eLife.

[23]  E. Ashley,et al.  Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in Thailand , 2014, CPT: pharmacometrics & systems pharmacology.

[24]  David L. Smith,et al.  Geographical variation in Plasmodium vivax relapse , 2014, Malaria Journal.

[25]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[26]  N. White,et al.  The activation of vivax malaria hypnozoites by infectious diseases. , 2013, The Lancet. Infectious diseases.

[27]  T. Speed,et al.  A High Force of Plasmodium vivax Blood-Stage Infection Drives the Rapid Acquisition of Immunity in Papua New Guinean Children , 2013, PLoS neglected tropical diseases.

[28]  N. White Determinants of relapse periodicity in Plasmodium vivax malaria , 2011, Malaria Journal.

[29]  T. Bousema,et al.  Adjusting for heterogeneity of malaria transmission in longitudinal studies. , 2011, The Journal of infectious diseases.

[30]  N. Laird,et al.  Positively Selected G6PD-Mahidol Mutation Reduces Plasmodium vivax Density in Southeast Asians , 2009, Science.

[31]  J. Baird,et al.  Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. , 2009, The Lancet. Infectious diseases.

[32]  K. Marsh,et al.  Analysis of Immunity to Febrile Malaria in Children That Distinguishes Immunity from Lack of Exposure , 2009, Infection and Immunity.

[33]  I. Mueller,et al.  The risk of malarial infections and disease in Papua New Guinean children. , 2007, The American journal of tropical medicine and hygiene.

[34]  R. Gray Modeling Survival Data: Extending the Cox Model , 2002 .

[35]  K. Dietz,et al.  Malaria therapy reinoculation data suggest individual variation of an innate immune response and independent acquisition of antiparasitic and antitoxic immunities. , 2002, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[36]  V. Sharma,et al.  Studies on the Plasmodium vivax relapse pattern in Delhi, India. , 1998, The American journal of tropical medicine and hygiene.

[37]  P. Grambsch,et al.  A Package for Survival Analysis in S , 1994 .

[38]  J. Beier,et al.  Sporozoite transmission by Anopheles freeborni and Anopheles gambiae experimentally infected with Plasmodium falciparum. , 1992, Journal of the American Mosquito Control Association.

[39]  L. H. Schmidt Compatibility of relapse patterns of Plasmodium cynomolgi infections in rhesus monkeys with continuous cyclical development and hypnozoite concepts of relapse. , 1986, The American journal of tropical medicine and hygiene.